促红细胞生成素；关于当前知识和新概念的综述
Erythropoietin; a review on current knowledge and new concepts.
作者信息
Tamadon Mohamad-Reza, Beladi-Mousavi Seyed Seifollah
机构信息
Department of Internal Medicine, Semnan University of Medical Sciences, Semnan, Iran.
Department of Internal Medicine, Ahvaz Jundishapour University of Medical Sciences, Ahvaz, Iran.
出版信息
J Renal Inj Prev. 2013 Oct 10;2(4):119-21. doi: 10.12861/jrip.2013.38. eCollection 2013.
Abstract
Chronic kidney disease (CKD) is a worldwide health problem. However, despite to new routes of dialysis, mortality and morbidity is high. One of the most common symptom of CKD is anemia, especially is more obvious in stages 3 and 4. In this review, we compared the effects of erythropoietin and anemia correction on kidney function (GFR) by investigating in various studies. Despite extensive studies in this category, still we do not sure about the effects of erythropoietin and anemia correction on the glomerular filtration rate.
摘要
慢性肾脏病（CKD）是一个全球性的健康问题。然而，尽管有了新的透析途径，死亡率和发病率仍然很高。CKD最常见的症状之一是贫血，尤其是在3期和4期更为明显。在本综述中，我们通过研究各项研究来比较促红细胞生成素和纠正贫血对肾功能（肾小球滤过率）的影响。尽管对此类进行了广泛研究，但我们仍不确定促红细胞生成素和纠正贫血对肾小球滤过率的影响。
相似文献
1
Erythropoietin; a review on current knowledge and new concepts.
J Renal Inj Prev. 2013 Oct 10;2(4):119-21. doi: 10.12861/jrip.2013.38. eCollection 2013.
2
Renal anemia and hydration status in non-dialysis chronic kidney disease: Is there a link?
J Med Life. 2018 Oct-Dec;11(4):293-298. doi: 10.25122/jml-2019-0002.
3
Attitude of physicians in Saudi Arabia towards anemia treatment strategies in patients with chronic kidney disease.
Saudi J Kidney Dis Transpl. 2007 Mar;18(1):65-72.
4
2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
Ther Apher Dial. 2010 Jun;14(3):240-75. doi: 10.1111/j.1744-9987.2010.00836.x.
5
Stabilization of glomerular filtration rate in advanced chronic kidney disease: a two-year follow-up of a cohort of chronic kidney disease patients stages 4 and 5.
Adv Chronic Kidney Dis. 2007 Jan;14(1):105-12. doi: 10.1053/j.ackd.2006.07.009.
6
Epidemiology of chronic kidney disease and anemia.
J Am Med Dir Assoc. 2006 Nov;7(9 Suppl):S3-6; quiz S17-21. doi: 10.1016/j.jamda.2006.09.004.
7
Influence of the 6-month anemia therapy with erythropoietin on renal function and some hemodynamic parameters in predialysis patients.
Pol Arch Med Wewn. 2009 Jan-Feb;119(1-2):45-51.
8
[Clinical relevance of anemia treatment in patients with chronic kidney disease].
Acta Med Croatica. 2012 Jul;66(3):193-202.
9
Methoxy Polyethylene Glycol-Epoetin Beta as a Novel Erythropoiesis Stimulating Agent with Possible Nephroprotective and Cardiovascular Protective Effects in Non-Dialysis Chronic Kidney Disease Patients.
Curr Pharm Biotechnol. 2017;18(4):303-308. doi: 10.2174/1389201018666170127104801.
10
The role of comprehensive renal clinic in chronic kidney disease stabilization and management: The Northwestern experience.
Semin Nephrol. 2002 Nov;22(6):526-32. doi: 10.1053/snep.2002.35970.
引用本文的文献
1
Pulmonary hypertension among patients undergoing hemodialysis.
J Renal Inj Prev. 2016 Dec 4;6(2):122-126. doi: 10.15171/jrip.2017.24. eCollection 2017.
2
Prevalence and predictors of atherosclerotic renal artery stenosis in hypertensive patients undergoing simultaneous coronary and renal artery angiography; a cross-sectional study.
J Renal Inj Prev. 2016 Feb 18;5(1):34-8. doi: 10.15171/jrip.2016.08. eCollection 2016.
3
Contrast induced nephropathy among patients with normal renal function undergoing coronary angiography.
J Renal Inj Prev. 2016 Feb 26;5(1):21-4. doi: 10.15171/jrip.2016.05. eCollection 2016.
4
Arteriovenous Fistula Recirculation in Hemodialysis.
Nephrourol Mon. 2015 Jul 22;7(4):e27474. doi: 10.5812/numonthly.27474. eCollection 2015 Jul.
5
Diabetes and end-stage renal disease; a review article on new concepts.
J Renal Inj Prev. 2015 Jun 1;4(2):28-33. doi: 10.12861/jrip.2015.07. eCollection 2015.
6
Protective effects of metformin on renal tubular cells.
Iran Red Crescent Med J. 2014 Sep 5;16(9):e11662. doi: 10.5812/ircmj.11662. eCollection 2014 Sep.
7
Erythropoietin and renal protection.
Daru. 2013 Dec 20;21(1):78. doi: 10.1186/2008-2231-21-78.
本文引用的文献
1
Erythropoietin ameliorates genetamicin-induced renal toxicity: A biochemical and histopathological study.
J Nephropathol. 2012 Jul;1(2):109-16. doi: 10.5812/nephropathol.7533. Epub 2012 Jul 1.
2
Erythropoietin; bright future and new hopes for an old drug.
J Nephropathol. 2012 Jul;1(2):81-2. doi: 10.5812/nephropathol.7475. Epub 2012 Jul 1.
3
Influence of the 6-month anemia therapy with erythropoietin on renal function and some hemodynamic parameters in predialysis patients.
Pol Arch Med Wewn. 2009 Jan-Feb;119(1-2):45-51.
4
In vivo and in vitro effects of simvastatin on inflammatory markers in pre-dialysis patients.
Nephrol Dial Transplant. 2006 Feb;21(2):337-44. doi: 10.1093/ndt/gfi224. Epub 2005 Oct 25.
5
Renal function, erythropoietin, and anemia of older persons: the InCHIANTI study.
Arch Intern Med. 2005 Oct 24;165(19):2222-7. doi: 10.1001/archinte.165.19.2222.
6
Effects of atorvastatin on low-density lipoprotein cholesterol phenotype and C-reactive protein levels in patients undergoing long-term dialysis.
Pharmacotherapy. 2005 Mar;25(3):335-44. doi: 10.1592/phco.25.3.335.61599.
7
Effects of atorvastatin on triglyceride-rich lipoproteins, low-density lipoprotein subclass, and C-reactive protein in hemodialysis patients.
Metabolism. 2004 Sep;53(9):1113-7. doi: 10.1016/j.metabol.2004.01.011.
8
The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study.
J Clin Pathol. 2004 Jul;57(7):728-34. doi: 10.1136/jcp.2003.012989.
9
Update on interleukin-6 and its role in chronic renal failure.
Nephrol Dial Transplant. 2003 Jun;18(6):1042-5. doi: 10.1093/ndt/gfg111.
10
Mortality, malnutrition, and atherosclerosis in ESRD: what is the role of interleukin-6?
Kidney Int Suppl. 2002 May(80):103-8. doi: 10.1046/j.1523-1755.61.s80.19.x.
Zotero 插件